This past February and March, Bruker Cellular Analysis, in partnership with BioProcess International, hosted a dynamic two-part webinar series โ Pushing the Boundaries in Cell Line Development โ spotlighting the capabilities of the Beaconยฎ Optofluidic platform for cell line development (CLD). Now available on demand, these sessions offer a front-row view into how cutting-edge technology is reshaping the CLD process.
In the opening session, โLight Boxes and Beyond: Maximizing Confidence in Clone Selection Using the Beacon Optofluidic System,โ GSKโs Holly Corrigall, Ph.D. shared how her team is using advanced digital tools, custom assays, and AI-driven models to accelerate and de-risk clone selection. From bispecific antibody screening with Spotlightโข reagents to predictive modeling with the Beacon Ranking Tool (BRT), her talk illustrated how GSK is building a โpredict-firstโ CLD workflow โ delivering high-confidence clones faster and with fewer resources.
The second webinar, โThe Physics and Technology Underlying the Beacon Platform for Cell Line Development,โ led by Or Gadish, Ph.D. from Bruker Cellular Analysis, dove into the core technology driving these breakthroughs. He provided an inside look at the physics behind the Beacon platform โ highlighting how innovations like Opto-Electropositioning (OEPยฎ), NanoPenยฎ chambers, and real-time, high-precision assays come together to enable fast, traceable, and automated CLD workflows. The result? End-to-end clone selection in as little as six weeks post-single cell cloning.
Whether youโre working on mAbs, bispecifics, or custom protein formats, this series showcases how the Beacon platform is empowering teams to make faster, smarter, and more confident decisions in CLD.
Donโt miss the chance to watch both sessions on demand and see how the Beacon platform is pushing the boundaries of whatโs possible in CLD.
Watch the first session on demand
